Denosumab e chirurgia orale
L'anticorpo monoclonale che ferma gli osteoclasti senza legarsi all'osso. Effetto reversibile, ma l'osteonecrosi c'è, e la sospensione porta con sé il rebound delle fratture vertebrali. La letteratura sulla finestra chirurgica è recente e ancora sottile.
- Lavori indicizzati
- 300
- Dal primo lavoro
- 2000
- Elenco aggiornato
- 22 settembre 2026
Quanto se ne scrive
Articoli pubblicati per anno. Nell’ultimo decennio ne sono usciti 3.9× rispetto ai dieci anni precedenti.
Revisioni sistematiche, meta-analisi e consensus
Dove la letteratura tira le somme. Se hai poco tempo, si comincia da qui.
- 1.
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials
Qi W, Tang L, He A, et al. Int J Clin Oncol. 2014;19(2):403-410
213 citazioni PubMed 23605142 doi:10.1007/s10147-013-0561-6
- 2.
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado J, et al. Clin Oral Implants Res. 2016;27(3):367-75
164 citazioni PubMed 25639776 doi:10.1111/clr.12556
- 3.
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
Limones Á, Sáez-Alcaide L, Díaz-Parreño S, et al. Med Oral Patol Oral Cir Bucal. 2020;25(3):e326-e336
132 citazioni PubMed 32271321 doi:10.4317/medoral.23324 testo libero
- 4.
Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S, Lumachi F, Stellini E, et al. Anticancer Res. 2013;33(5):1793-7
111 citazioni PubMed 23645723
- 5.
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
Karlsson L, Lundkvist J, Psachoulia E, et al. Osteoporos Int. 2015;26(10):2401-2411
88 citazioni PubMed 26282229 doi:10.1007/s00198-015-3253-4 testo libero
- 6.
The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J, Ettinger K, Naumann E, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(6):671-6
88 citazioni PubMed 23159111 doi:10.1016/j.oooo.2012.08.439
- 7.
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.
King R, Tanna N, Patel V. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(4):289-299
86 citazioni PubMed 30713092 doi:10.1016/j.oooo.2018.11.012
- 8.
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S, Gaudin R, Weiser J, et al. J Craniomaxillofac Surg. 2018;46(9):1515-1525
64 citazioni PubMed 29983309 doi:10.1016/j.jcms.2018.05.046
I lavori più citati di sempre
I riferimenti che tutti gli altri citano. Alcuni hanno trent’anni e restano il fondamento della tecnica.
- 9.
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo T, Felsenfeld A, Tetradis S. J Oral Maxillofac Surg. 2010;68(5):959-963
271 citazioni PubMed 20149510 doi:10.1016/j.joms.2009.10.010 testo libero
- 10.
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Miller P, Pannacciulli N, Brown JP, et al. J Clin Endocrinol Metab. 2016;101(8):3163-3170
232 citazioni PubMed 27270237 doi:10.1210/jc.2016-1801 testo libero
- 11.
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials
Qi W, Tang L, He A, et al. International Journal of Clinical Oncology. 2014;19:403-410
213 citazioni PubMed 23605142 doi:10.1007/s10147-013-0561-6
- 12.
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado J, et al. Clinical Oral Implants Research. 2016;27(3):367-75
164 citazioni PubMed 25639776 doi:10.1111/clr.12556
- 13.
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
Limones Á, Sáez-Alcaide L, Díaz-Parreño S, et al. Medicina Oral. 2020;25:e326-e336
132 citazioni PubMed 32271321 doi:10.4317/medoral.23324 testo libero
- 14.
Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S, Lumachi F, Stellini E, et al. Anticancer Research. 2013;33(5):1793-7
111 citazioni PubMed 23645723
- 15.
Denosumab-related osteonecrosis of the jaw.
Diz P, López-Cedrún J, Arenaz J, et al. J Am Dent Assoc. 2012;143(9):981-4
97 citazioni PubMed 22942143 doi:10.14219/jada.archive.2012.0323 testo libero
- 16.
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis
Judith E, Daniel L, John-Patrik B, et al. J Bone Miner Res. 2021;37(2):340-348
92 citazioni PubMed 34787342 doi:10.1002/jbmr.4472 testo libero
- 17.
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
Karlsson L, Lundkvist J, Psachoulia E, et al. Osteoporosis International. 2015;26:2401-2411
88 citazioni PubMed 26282229 doi:10.1007/s00198-015-3253-4 testo libero
- 18.
The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J, Ettinger K, Naumann E, et al. Oral surgery, oral medicine, oral pathology and oral radiology. 2012;114(6):671-6
88 citazioni PubMed 23159111 doi:10.1016/j.oooo.2012.08.439
- 19.
Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
Watts N, Grbic J, Binkley N, et al. J Clin Endocrinol Metab. 2019;104(6):2443-2452
87 citazioni PubMed 30759221 doi:10.1210/jc.2018-01965 testo libero
- 20.
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.
King R, Tanna N, Patel V. Oral surgery, oral medicine, oral pathology and oral radiology. 2019;127(4):289-299
86 citazioni PubMed 30713092 doi:10.1016/j.oooo.2018.11.012
- 21.
Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok C, Ho L, Ma K. Bone. 2015;75:222-8
82 citazioni PubMed 25761434 doi:10.1016/j.bone.2015.03.002
- 22.
Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
Parthan A, Kruse M, Yurgin N, et al. Appl Health Econ Health Policy. 2013;11(5):485-497
81 citazioni PubMed 23868102 doi:10.1007/s40258-013-0047-8
- 23.
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M, Sada H, Sugiura Y, et al. Biol Pharm Bull. 2015;38(12):1850-5
73 citazioni PubMed 26632176 doi:10.1248/bpb.b15-00385 testo libero
- 24.
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone
Uday S, Gaston C, Rogers L, et al. J Clin Endocrinol Metab. 2018;103(2):596–603
71 citazioni PubMed 29211870 doi:10.1210/jc.2017-02025 testo libero
- 25.
Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
Hiligsmann M, Reginster J. Pharmacoeconomics. 2011;29(10):895-911
71 citazioni PubMed 21692551 doi:10.2165/11539980-000000000-00000 testo libero
- 26.
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S, Hayashida S, Funahara M, et al. PLoS One. 2018;13(7):e0201343
70 citazioni PubMed 30048523 doi:10.1371/journal.pone.0201343 testo libero
- 27.
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Ebina K, Hashimoto J, Kashii M, et al. J Bone Miner Metab. 2015;35(1):91-98
66 citazioni PubMed 26762133 doi:10.1007/s00774-015-0731-x testo libero
- 28.
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S, Gaudin R, Weiser J, et al. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2018;46(9):1515-1525
64 citazioni PubMed 29983309 doi:10.1016/j.jcms.2018.05.046
Gli ultimi tre anni
Cosa è uscito di recente, ordinato per quanto è già stato citato.
- 29.
Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
Liu F, Luk K, Chen Y. Osteoporos Int. 2023;34(10):1729-1737
37 citazioni PubMed 37326685 doi:10.1007/s00198-023-06818-3 testo libero
- 30.
Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Zhang C, Shen G, Li H, et al. Spec Care Dentist. 2023;44(2):530-541
21 citazioni PubMed 37219080 doi:10.1111/scd.12877
- 31.
Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis
Masuda S, Fukasawa T, Matsuda S, et al. Ann Intern Med. 2025;178(2):167-176
17 citazioni PubMed 39761590 doi:10.7326/annals-24-03237
- 32.
A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab
Bracchi P, Zecca E, Brunelli C, et al. Cancer Med. 2023;12(17):18317-18326
17 citazioni PubMed 37559413 doi:10.1002/cam4.6429 testo libero
- 33.
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
Fu P, Shen C, Yang S, et al. Sci Rep. 2023;13(1):8403
17 citazioni PubMed 37225727 doi:10.1038/s41598-023-35308-z testo libero
- 34.
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
Yuan C, Liang Y, Zhu K, et al. J Orthop Surg Res. 2023;18(1):447
17 citazioni PubMed 37349750 doi:10.1186/s13018-023-03920-4 testo libero
- 35.
Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
Yang J, Guo X, Cui Z, et al. Front Endocrinol (Lausanne). 2024;15:1431676
13 citazioni PubMed 39286276 doi:10.3389/fendo.2024.1431676 testo libero
- 36.
High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients
Moon C, Kim H, Park J, et al. Support Care Cancer. 2024;32(12):774
13 citazioni PubMed 39499349 doi:10.1007/s00520-024-08974-6
- 37.
Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review
Latorre CG, Atalah CN, Baburizza MM. Oral Maxillofac Surg. 2024;28(3):1029-1045
11 citazioni PubMed 38539018 doi:10.1007/s10006-024-01245-y
- 38.
Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
Hosteng KR, Peter ME, Chakrabarti A, et al. Bone. 2023;177:116925
11 citazioni PubMed 37797711 doi:10.1016/j.bone.2023.116925
Su Bonebenders
Quello che il Dr. Bruschi ha scritto su questo tema, in italiano e con le sue mani.
Come è fatto questo elenco
I lavori arrivano da Semantic Scholar, il catalogo dell’Allen Institute for AI. Entrano solo i titoli che contengono uno di questi termini (denosumab e osteonecrosis; denosumab e jaw; denosumab e dental; denosumab e oral; denosumab e discontinuation) e che hanno un identificativo PubMed o un DOI. Rivista, fascicolo e pagine sono uniformati con PubMed. L’ordinamento è per numero di citazioni ricevute: dice quanto un lavoro è stato usato dagli altri ricercatori, non quanto è vero. La selezione è automatica e non sostituisce una lettura critica. Elenco rigenerato ogni mese; ultimo cambiamento il 22 settembre 2026.